Basel, Switzerland, September 18, 2025 - Roche, a leading pharmaceutical company with the stock symbols SIX: RO, ROG and OTCQX: RHHBY, announced its definitive merger agreement to acquire 89bio, Inc., a clinical-stage biopharmaceutical firm listed on Nasdaq under ETNB. The focus of 89bio is on developing groundbreaking therapies for liver and cardiometabolic diseases. Notably, their lead product, pegozafermin, an FGF21 analog, is in advanced stages of development for treating MASH in patients with moderate to severe fibrosis (F2 and F3 stages) and cirrhotic patients (F4 stage). The acquisition deal is set to be finalized in the fourth quarter of 2025.